MedTrace Logo

The Effect of Neprilysin (LCZ696) on Exercise Tolerance in Patients With Heart Failure

NCT03190304 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 52

Last updated 2020-10-22

No results posted yet for this study

Summary

Studies with new drugs in the treatment of heart failure (HF), such as the combination of valsartan/sacubitril, also known as LCZ696, have demonstrated important clinical impact on the morbidity and mortality outcomes in HF population. However, the effect of LCZ696 on the pathophysiological mechanisms of HF such as exercise tolerance (peak VO2) and peripheral muscle blood flow is not known. Since LCZ696 is a new drug with promising effects on the treatment of HF, the objective of the present study will be to evaluate the effect of LCZ696 in patients with HF on: 1) peak VO2, 2) 6-minute walk test, 3) peripheral muscle blood flow, 4) muscle strength, and 5) body composition.

Conditions

  • Heart Failure
  • Exercise Tolerance
  • Vasodilation
  • Body Composition
  • Muscle Strength

Interventions

DRUG

Neprilysin

To compare the effect of Enalapril and Neprilysin on exercise tolerance in patients with heart failure

DRUG

Enalapril

To compare the effect of Enalapril and Neprilysin on exercise tolerance in patients with heart failure

Sponsors & Collaborators

  • University of Sao Paulo General Hospital

    lead OTHER

Principal Investigators

  • Antonio P Barretto, PhD · Heart Institute (InCor), University of Sao Paulo Medical School

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-06-14
Primary Completion
2020-09-14
Completion
2020-09-23

Countries

  • Brazil

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03190304 on ClinicalTrials.gov